已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

10 Years of belimumab experience: What have we learnt?

贝里穆马布 医学 狼疮性肾炎 耐受性 临床试验 内科学 系统性红斑狼疮 不利影响 疾病 B细胞激活因子 免疫学 抗体 B细胞
作者
Roger A. Levy,Tania Gonzalez‐Rivera,Munther A. Khamashta,Norma Lynn Fox,Angela R. Jones-Leone,Bernie Rubin,Susan W. Burriss,Kerry Gairy,André van Maurik,David A. Roth
出处
期刊:Lupus [SAGE Publishing]
卷期号:30 (11): 1705-1721 被引量:134
标识
DOI:10.1177/09612033211028653
摘要

Systemic lupus erythematosus (SLE) is a chronic autoimmune inflammatory disease affecting both adults and children. Belimumab is the only biologic approved for SLE, and the first in a class of drugs known as B-lymphocyte stimulator-specific inhibitors. The introduction of intravenous belimumab in 2011 was a major advance, being the first new therapy approved for SLE in over 50 years. As of April 2021, more than 7200 people with SLE have received belimumab in clinical studies, and it is approved in over 75 countries for the treatment of adults with SLE. A subcutaneous, self-injectable belimumab formulation was licensed in 2017 by both the US Food and Drug Administration (FDA) and European Medicines Agency (EMA). Belimumab was then approved for use in children in Europe, the USA and Japan in 2019, and China and Brazil in 2020. Recently, belimumab became the first FDA-approved drug for the treatment of adults with active lupus nephritis (LN), the most-common severe manifestation of SLE.Over the past 10 years, belimumab has established its position as a disease modifier in the SLE treatment paradigms. Robust evidence from randomised clinical studies and observational, real-world studies has demonstrated the tolerability and efficacy of belimumab for reducing disease activity and the risk of new, severe SLE flares. This enables patients to taper their glucocorticoid use, which limits damage accumulation. Significantly more patients with active LN met the criteria for renal responses and were at less risk of a renal-related event or death after receiving belimumab plus standard therapy, compared with standard therapy on top of mandatory steroid reduction. Ongoing clinical studies are evaluating belimumab's effectiveness in various indications beyond SLE. Post-marketing and registry studies are gathering additional data on key areas such as pregnancy outcomes after belimumab exposure and belimumab co-administration with other biologics.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
布拉德皮特厚完成签到,获得积分10
刚刚
1秒前
李健的小迷弟的应助被Judy采纳,获得10
1秒前
2秒前
3921337477发布了新的文献求助10
2秒前
3秒前
3921337477发布了新的文献求助10
4秒前
圈圈发布了新的文献求助10
5秒前
blueblue完成签到,获得积分10
5秒前
山海不远发布了新的文献求助30
5秒前
所所的应助被EstAffectus采纳,获得200
6秒前
3921337477发布了新的文献求助10
6秒前
ding的应助被火焰迷踪采纳,获得10
6秒前
123完成签到,获得积分10
7秒前
RoyaAllen822发布了新的文献求助40
8秒前
www完成签到,获得积分10
8秒前
个性向卉发布了新的文献求助10
8秒前
思源的应助被清秀爆米花采纳,获得30
8秒前
gtgyh发布了新的文献求助10
9秒前
3921337477发布了新的文献求助10
9秒前
fantasy的应助被blueblue采纳,获得10
10秒前
10秒前
3921337477发布了新的文献求助10
11秒前
13秒前
残忆思完成签到 ,获得积分10
13秒前
秋风的应助被monster采纳,获得10
13秒前
3921337477发布了新的文献求助10
13秒前
思源的应助被rexleeeeee采纳,获得10
14秒前
15秒前
科研通AI6.2的应助被开朗念波采纳,获得10
15秒前
15秒前
盒子发布了新的文献求助30
18秒前
aaaa完成签到,获得积分10
19秒前
牛婷发布了新的文献求助10
19秒前
李健的应助被布洛芬采纳,获得10
19秒前
阿蛋完成签到,获得积分10
22秒前
lishuang发布了新的文献求助10
23秒前
25秒前
思源的应助被monster采纳,获得10
25秒前
25秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8184536
求助须知:如何正确求助?哪些是违规求助? 9573526
关于积分的说明 21832132
捐赠科研通 7781791
什么是DOI,文献DOI怎么找? 3434376
关于科研通互助平台的介绍 2558490
邀请新用户注册赠送积分活动 2480989